Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Did this congressman benefit from a stock buy just before FDA approval?

Oct 7, 2024, 10:44 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Gottheimer’s investment and upcoming FDA news likely drive positive sentiment, similar gains followed past pharma announcements.

AI summary

What happened, with direct paths to the underlying reporting

Representative Gottheimer disclosed a September 25 investment in CRNX. CRNX stock rose 11.66% since Gottheimer's purchase at $50.58. Analysts unanimously rate CRNX as 'Buy', with an average $71.50 price target. CRNX is expected to launch a daily oral treatment for acromegaly. Gottheimer's investment precedes a significant FDA announcement for CRNX.

Representative Gottheimer disclosed a September 25 investment in CRNX.
CRNX stock rose 11.66% since Gottheimer's purchase at $50.58.
Analysts unanimously rate CRNX as 'Buy', with an average $71.50 price target.
CRNX is expected to launch a daily oral treatment for acromegaly.
Gottheimer's investment precedes a significant FDA announcement for CRNX.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Did this congressman benefit from a stock buy just before FDA approval?

Vertex to acquire Crinetics for $85 per share in cash; CRNX surges

Vertex to buy Crinetics for about $10B, signaling a premium for CRNX

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates